Genewity

Executive Summary

Genewity is a Netherlands-based biotechnology company focused on developing autologous ex vivo stem cell gene therapies for severe, life-threatening rare pediatric diseases. Its lead program, executed by subsidiary Videja, targets Severe Combined Immunodeficiency (SCID), a genetic disorder that leaves infants without a functional immune system. The company's platform leverages AI-powered genomic data analysis to design personalized, one-time curative treatments that correct the root cause of disease. By utilizing the patient's own stem cells, Genewity aims to eliminate the risk of graft-versus-host disease and provide durable therapeutic benefit. As a pre-clinical stage company, Genewity is advancing its SCID program toward investigational new drug (IND)-enabling studies, with the goal of initiating first-in-human trials within the next few years. The company represents a promising approach to address high unmet medical needs in pediatric rare diseases, combining cutting-edge gene editing, stem cell biology, and artificial intelligence. While still early-stage, Genewity's focus on validated genetic targets and its strategic positioning in the Netherlands' vibrant biotech ecosystem provide a foundation for potential growth. The success of the company hinges on successful preclinical validation, securing funding for clinical translation, and eventual regulatory approval.

Upcoming Catalysts (preview)

• Q2 2027Preclinical proof-of-concept data for SCID gene therapy program70% success
• Q4 2026Series A financing round to support IND-enabling studies60% success
• Q3 2026Partnership with academic medical center for gene therapy delivery optimization50% success